Year

ANNUAL RESULTS

Logo

UNLIMITED

POTENTIAL

Currently viewing: 1.3 OPERATING (LOSS)/ PROFIT | Next: 1.4 Finance costs and finance income

1.3 OPERATING (LOSS)/ PROFIT

Notes

2026

R’000 

2025

R’000 

The following has been charged/(credited) in arriving at operating (loss)/ profit: 

Advertising and promotional expenses1  

211 961 

54 275 

Audit fees – services as auditors relating to the year-end audit2  

26 989 

19 379 

Audit fees – other3

1 677 

- 

Consulting fees4

146 702 

50 201 

Foreign exchange (gain)/loss  

(892)

1 578 

Gain on effective settlement of pre-existing relationships upon obtaining control1 of Cell C

2.2.1

(480 707)

– 

Gain on settlement by Cell C of leases with Dark Fibre Africa5

1.1 

(355 832)

– 

Impairment of inventory  

17 424 

8 034 

Insurance6  

34 137 

27 600 

IT infrastructure costs and computer-related costs7

85 136 

76 831 

Legal fees8  

4 417 

11 569 

Licence fees9

150 291 

87 076 

Loss on disposal of property, plant and equipment  

3 163 

1 998 

Loss on disposal of intangible assets

37 092 

– 

Loss on disposal of subsidiary – Cell C (including CEC)

2.2.2

6 027 454 

– 

Loss on disposal of subsidiary – other

105 060 

– 

Loss on in-substance written call option over Cell C shares issued to Sisonke Growth Partners Proprietary Limited

3.5 

140 000 

– 

Loss on written put option over Cell C shares issued to Nedbank and Lesaka

3.5 

141 117 

– 

Motor vehicle expenses10 

11 578 

11 450 

Software development and IT project costs

56 999 

70 390 

Staff training11  

45 528 

52 492 

Transaction costs related to the restructuring, unbundling and the listing of Cell C12

318 992 

– 

Travel – local and overseas13  

24 837 

17 544 

Impairments of goodwill comprise the following:

Impairment of goodwill arising on Glocell Distribution Proprietary Limited

4.1 

161 697 

– 

Impairment of goodwill – other

4.1 

38 895 

– 

200 592 

– 

Fair value movements comprise the following: 

Fair value gain on surety receivable 

3.5 

(2 200)

(2 883)

Net fair value gain on financial instruments 

3.5 

21 896 

(171 433)

Fair value gain on Preference shares B

3.5 

(242 637)

– 

(222 941)

(174 316)

Bad debts and expected credit loss comprise the following:  

Bad debts and expected credit loss on loans 

(9 469)

(284 981)

Bad debts and expected credit losses on trade receivables, other receivables and advances to customers  

224 994 

520 505 

215 525 

235 524 

Modification/derecognition of financial instruments 

comprise the following: 

TPC

(Gain)/loss on modification of financial liability – Class A Preference Shares 

3.4.2

(43 238)

18 769 

Gain on derecognition of financial liability – SPV5

3.4.2

(165 216)

– 

Loss on modification of financial liability – Gramercy

3.4.2

15 792 

– 

CEC

Loss on derecognition of financial assets measured at amortised cost 

– 

34 103 

(192 662)

52 872 

1 Included in 2026 is R150.6 million incurred by Cell C for the three-month period consolidated September to November 2025.
2 Included in 2026 is R4.8 million incurred by Cell C for the three-month period consolidated September to November 2025.
3 Included in 2026 is R1.7 million incurred by Cell C for the three-month period consolidated September to November 2025.
4 Included in 2026 is R76.6 million incurred by Cell C for the three-month period consolidated September to November 2025.
5 Included in 2026 is R355.8 million incurred by Cell C for the three-month period consolidated September to November 2025.
6 Included in 2026 is R8.9 million incurred by Cell C for the three-month period consolidated September to November 2025.
7 Included in 2026 is R6.2 million incurred by Cell C for the three-month period consolidated September to November 2025.
8 Included in 2026 is R0.9 million incurred by Cell C for the three-month period consolidated September to November 2025.
9 Included in 2026 is R59.6 million incurred by Cell C for the three-month period consolidated September to November 2025.
10 Included in 2026 is R1.9 million incurred by Cell C for the three-month period consolidated September to November 2025.
11 Included in 2026 is R2.0 million incurred by Cell C for the three-month period consolidated September to November 2025.
12 Included in 2026 is R232.5 million incurred by Cell C for the three-month period consolidated September to November 2025.
13 Included in 2026 is R2.1 million incurred by Cell C for the three-month period consolidated September to November 2025.